Why Drug Safety Should Not Take a Back Seat to Efficacy
2011
Why Drug Safety Should Not Take a Back Seat to Efficacy
Editorial
Author Information
Author(s): Virginia Barbour, Jocalyn Clark, Susan Jones, Melissa Norton, Paul Simpson, Emma Veitch
Primary Institution: Public Library of Science
Conclusion
The evaluation of drug safety should be prioritized alongside efficacy to prevent avoidable hospitalizations and deaths.
Supporting Evidence
- Drug safety evaluations have historically been considered less important than drug efficacy.
- Evidence suggests that drugs approved under rapid review may have more safety issues post-marketing.
- Systematic reviews of observational studies can provide valuable data on drug harms.
Takeaway
This article says that making sure drugs are safe is just as important as proving they work, so we should pay attention to both.
Potential Biases
There are concerns about potential conflicts of interest in studies funded by the pharmaceutical industry.
Limitations
The article discusses the challenges in evaluating drug safety but does not provide specific limitations of the studies mentioned.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website